{"id":6980,"date":"2022-11-30T07:07:10","date_gmt":"2022-11-30T01:37:10","guid":{"rendered":"https:\/\/vajiramandravi.com\/current-affairs\/?p=6980"},"modified":"2025-03-28T16:15:22","modified_gmt":"2025-03-28T10:45:22","slug":"incovacc","status":"publish","type":"post","link":"https:\/\/vajiramandravi.com\/current-affairs\/incovacc\/","title":{"rendered":"iNCOVACC"},"content":{"rendered":"<h2><strong>About iNCOVACC:<\/strong><\/h2>\n<ul>\n<li>It is developed by\u00a0<strong>Bharat Biotech International Limited.<\/strong><\/li>\n<li>It was developed in partnership with\u00a0<strong>Washington University, St Louis<\/strong>, which had designed and developed the recombinant adenoviral vectored construct and evaluated in pre-clinical studies for efficacy.<\/li>\n<li>The approval is under Restricted Use in\u00a0<strong>Emergency Situation for ages 18 and above in India, for heterologous booster doses.<\/strong><\/li>\n<li>iNCOVACC is a\u00a0<strong>recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised SARS-CoV-2 spike protein.<\/strong><\/li>\n<li>It is the world&#8217;s first intranasal vaccine to receive both primary series and heterologous booster approval.<\/li>\n<li>The vaccine candidate was evaluated in Phases I, II and III clinical trials with successful results and has been specifically formulated to allow intranasal delivery through nasal drops.<\/li>\n<li>It is stable at 2-8 degrees Celsius for easy storage and distribution.<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<hr \/>\n<p><strong>Source :\u00a0<\/strong><a href=\"https:\/\/newsonair.gov.in\/News?title=World%e2%80%99s-first-Intranasal-vaccine-iNCOVACC-gets-DCGI-approval-for-Covid-booster-doses&amp;id=451526\" target=\"_blank\" rel=\"nofollow noopener\">All India Radio<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>iNCOVACC is world&#8217;s first Intranasal Vaccinedeveloped by Bharat Biotech International Limited.<\/p>\n","protected":false},"author":5,"featured_media":6981,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":{"0":"post-6980","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-upsc-prelims-current-affairs","8":"no-featured-image-padding"},"acf":[],"_links":{"self":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/6980","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/comments?post=6980"}],"version-history":[{"count":0,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/posts\/6980\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/media\/6981"}],"wp:attachment":[{"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/media?parent=6980"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/categories?post=6980"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vajiramandravi.com\/current-affairs\/wp-json\/wp\/v2\/tags?post=6980"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}